These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17074629)

  • 1. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
    O'Connor AB
    J Pain; 2006 Nov; 7(11):867; author reply 867-8. PubMed ID: 17074629
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabetic peripheral neuropathic pain: recognition and management.
    Cole BE
    Pain Med; 2007 Sep; 8 Suppl 2():S27-32. PubMed ID: 17714113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?
    Russell JW
    Nat Clin Pract Neurol; 2006 Jan; 2(1):18-9. PubMed ID: 16932514
    [No Abstract]   [Full Text] [Related]  

  • 4. Opioid utilization and health-care costs among patients with diabetic peripheral neuropathic pain treated with duloxetine vs. other therapies.
    Wu N; Chen SY; Hallett LA; Boulanger L; Fraser KA; Patel CK; Zhao Y
    Pain Pract; 2011; 11(1):48-56. PubMed ID: 20602718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine (Cymbalta) for diabetic neuropathic pain.
    Med Lett Drugs Ther; 2005 Aug 15-29; 47(1215-1216):67-8. PubMed ID: 16103866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.
    Wu EQ; Birnbaum HG; Mareva MN; Le TK; Robinson RL; Rosen A; Gelwicks S
    J Pain; 2006 Jun; 7(6):399-407. PubMed ID: 16750796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
    Perahia DG; Pritchett YL; Desaiah D; Raskin J
    Int Clin Psychopharmacol; 2006 Nov; 21(6):311-7. PubMed ID: 17012978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of treatment in diabetic peripheral neuropathic pain.
    Robinson-Papp J; Simpson DM
    Pain Med; 2007 Sep; 8 Suppl 2():S43-9. PubMed ID: 17714115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
    Bellows BK; Dahal A; Jiao T; Biskupiak J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does pain cause the perception of fatigue in patients with chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
    Fishbain DA; Hall JA; Risser RC; Gonzales JS
    Pain Pract; 2009; 9(5):354-62. PubMed ID: 19500272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK.
    Beard SM; McCrink L; Le TK; Garcia-Cebrian A; Monz B; Malik RA
    Curr Med Res Opin; 2008 Feb; 24(2):385-99. PubMed ID: 18157921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the impact of pharmacologic intervention on the quality of life in diabetic peripheral neuropathic pain and fibromyalgia.
    Wu SC; Wrobel JS; Armstrong DG
    Pain Med; 2007 Sep; 8 Suppl 2():S33-42. PubMed ID: 17714114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine.
    Fishbain DA; Hall J; Meyers AL; Gonzales J; Mallinckrodt C
    J Pain Symptom Manage; 2008 Dec; 36(6):639-47. PubMed ID: 18504092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study on comparative efficacy and cost effectiveness of Pregabalin and Duloxetine used in diabetic neuropathic pain.
    Roy MK; Kuriakose AS; Varma SK; Jacob LA; Beegum NJ
    Diabetes Metab Syndr; 2017; 11(1):31-35. PubMed ID: 27484440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review.
    Barrett AM; Lucero MA; Le T; Robinson RL; Dworkin RH; Chappell AS
    Pain Med; 2007 Sep; 8 Suppl 2():S50-62. PubMed ID: 17714116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
    Ziegler D; Pritchett YL; Wang F; Desaiah D; Robinson MJ; Hall JA; Chappell AS
    Diabetes Care; 2007 Mar; 30(3):664-9. PubMed ID: 17327338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid use and healthcare costs among patients with DPNP initiating duloxetine versus other treatments.
    Chen S; Wu N; Fraser K; Boulanger L; Zhao Y
    Curr Med Res Opin; 2010 Oct; 26(10):2507-16. PubMed ID: 20831456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating diabetic peripheral neuropathic pain.
    Lindsay TJ; Rodgers BC; Savath V; Hettinger K
    Am Fam Physician; 2010 Jul; 82(2):151-8. PubMed ID: 20642268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms.
    McIntyre RS; Konarski JZ
    Expert Opin Pharmacother; 2005 May; 6(5):707-13. PubMed ID: 15934897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of duloxetine on primary pain symptoms in Parkinson disease.
    Djaldetti R; Yust-Katz S; Kolianov V; Melamed E; Dabby R
    Clin Neuropharmacol; 2007; 30(4):201-5. PubMed ID: 17762316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.